Cabergoline: a long-acting dopamine agonist, and when prolactin actually needs treating

Highly effective at the thing it does, and prescribed for a number that is wrong more often than most. The pharmacology is simple; the difficulty is deciding whether the result that prompted it was real.

What it does, and why twice weekly

Established clinical use Prolactin release from the pituitary is under continuous inhibitory control by dopamine — unusually, the default state is suppression rather than stimulation. Cabergoline is a dopamine D2 receptor agonist that supplies that inhibition pharmacologically, and it is the first-line treatment for hyperprolactinaemia and for prolactin-secreting pituitary adenomas, where it both normalises the hormone and shrinks the tumour.

The app models its half-life at about two and a half days, which is very long for this class and is why a twice-weekly schedule works where other dopamine agonists need daily dosing. It also means the level accumulates for a couple of weeks before it settles, so an effect assessed at one week is being assessed before the drug has finished arriving.

Most high prolactin results are not what they look like

Established clinical use Prolactin is one of the easiest hormones to elevate by accident. It rises with the stress of venipuncture itself, with sleep, with exercise, with a meal, with nipple stimulation, and with a long list of common medications — antipsychotics and some antidepressants and antiemetics among them. A mildly high value on a single draw is more often one of those than a pituitary problem, which is why the standard response is to repeat it under controlled conditions rather than to treat it.

The other trap is macroprolactin: prolactin bound into large immune complexes that most immunoassays detect but which is biologically inactive. Someone with macroprolactinaemia has a genuinely high assay result and no disease, and the laboratory test that separates them has to be requested. Treating that patient achieves nothing except side effects. The prolactin page covers both problems and how the units differ between labs.

Off-label or community practice In hormone-therapy contexts, cabergoline is often used against prolactin elevated by progestogenic anabolic compounds — which this site does not publish pages for — or by higher-dose gonadotropin use. The app’s own protocol note is explicit that it should not be used prophylactically without a confirmed lab result, and that is the right instinct: this is a drug that treats a number, so the number has to be real first.

The valve question, stated in proportion

Established clinical use Ergot-derived dopamine agonists are associated with cardiac valve fibrosis, and the finding is real. What matters is the dose. The association was established in Parkinson’s disease, where cumulative doses run an order of magnitude or more above what is used for hyperprolactinaemia, and studies at endocrine doses have largely not found clinically significant valvulopathy. That is reassuring rather than conclusive, and it is why guidance for long-term use at higher endocrine doses includes periodic echocardiography.

The commoner effects are nausea, which is worst at initiation and usually settles, orthostatic dizziness, and fatigue. Impulse-control problems — a recognised class effect of dopamine agonists — are rare at these doses but worth naming, because the person experiencing one is often the last to attribute it to a tablet taken twice a week.

All of it is a prescribing decision made against a confirmed result. Anything on this page that you are actually experiencing belongs with the clinician who prescribed it, who is the only person who can weigh it against why you started.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Cabergoline, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Sensitive versus standard estradiol
• Prolactin

Drawbacks and risks the app records

From the app’s own entry. The fourth item — that it is not needed unless prolactin is genuinely elevated — is the one that prevents the other five.

• Heart valve concerns at high doses (Parkinson's disease doses — much higher than TRT use)
• Nausea, especially initially
• Fatigue possible
• Orthostatic hypotension
• Not needed unless prolactin is actually elevated
• Cardiac monitoring at higher doses recommended

Interaction rules that name Cabergoline

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

How high does prolactin have to be before it means something?

That is a clinician call against your own lab’s interval, and it depends on how the sample was taken. What is standard is that a mildly high value is repeated under controlled conditions, and that macroprolactin is excluded, before anything is treated.

How long until it works?

Prolactin usually falls within days and normalises over weeks. Because the half-life is long, the level of the drug itself is still accumulating for the first couple of weeks, so early assessments underestimate the eventual effect.

Is an echocardiogram necessary?

Guidance generally reserves it for higher doses or long-term use, on the basis that the valve association was established at Parkinson’s-disease doses far above endocrine ones. Whether it applies to a particular person and schedule is a prescribing decision.

Does it affect testosterone?

Indirectly. High prolactin suppresses gonadotropin release and therefore testosterone, so correcting a genuinely elevated prolactin can raise it. Correcting a normal prolactin does nothing useful. The LH and FSH page covers that axis.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.